Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mylan Poised To Launch Its First US Biosimilar, With A Stacked Pipeline Behind It

Executive Summary

A biosimilar of Amgen's Neulasta appears on track for FDA approval by the June 4 action date, management said during an investor briefing that showcased Mylan's expansive biosimilar pipeline. Mid- to late-stage copies of products like Advair, Symbicort, Herceptin, Humira, Avastin, Rituxan, Eylea and Botox highlight the strategic direction Mylan moved in nearly a decade ago. 

You may also be interested in...



Mylan Looks To Expedite Biosimilar Humira in EU Through Kyowa Deal

Mylan has acquired commercial rights in Europe to Kyowa Hakko Kirin's biosimilar adalimumab, paving the way to an early market entry through the product, which could be approved in the second half of this year. But might there be a shift in the commercialization outlook for its partnered adalimumab with Biocon?

Mylan Set To Develop Biosimilar Botox In Deal With Revance

Mylan's revenue was down due to issues in the North American market, but the company is looking forward to development of new products to balance out losses in the future, including a newly announced Botox biosimilar.

Provider Consortium Will Try 'DIY' Solution To Generic Shortages, Pricing

Four health care systems representing 280 hospitals, with input from the US Department of Veterans Affairs, plan to make and sell their own generic drugs, focusing on those vitally needed by hospitals, with "appropriate" pricing.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB001586

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel